Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 18, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 18 January 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global...
-
Jan 18, 2022
CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd. MELBOURNE, Australia and ST. GALLEN, Switzerland. CSL Behring AG, Berne,...
-
Jan 18, 2022Ad hoc release pursuant to Art. 53 LR, Switzerland
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender...
-
Dec 21, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer)...
-
Dec 20, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Abbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled St. Gallen, Switzerland, and...
-
Dec 16, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Focus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product...
-
Dec 15, 2021
KING OF PRUSSIA, PA, USA – DECEMBER 15, 2021 – Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific...
-
Dec 14, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent...
-
Dec 14, 2021
Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron...
-
Dec 14, 2021
Melbourne, 14 December 2021 – CSL Limited (ASX:CSL) and its vaccine business, Seqirus, today reaffirms a strong commitment to accelerating its proprietary next-generation self-amplifying mRNA...